A Multicenter, Randomized, Single-blind Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Latest Information Update: 23 May 2025
At a glance
- Drugs XH S003 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Acronyms XH-S003-II-101
- Sponsors S-Infinity Pharmaceuticals
Most Recent Events
- 23 May 2025 New trial record